Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2736-2753

  Yang, Shun Fa ^a,b   Lee, Wei Jiunn ^c   Tan, Peng ^d   Tang, Chih Hsin ^e   Hsiao, Michael ^f   Hsieh, Feng Koo ^g   Chien, Ming Hsien ^c,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f GENOMICS RESEARCH CENTER   (Taiwan)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CREB; Metastasis; miR 328; MMP 2; Osteosarcoma; Resveratrol

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GELATINASE A; MICRORNA; MICRORNA 328; MITOGEN ACTIVATED PROTEIN KINASE P38; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; CREBBP PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MIRN328 MICRORNA, HUMAN; MMP2 PROTEIN, HUMAN; STILBENE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TISSUE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENETIC REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIMARY TUMOR; PROTEIN DNA BINDING; PROTEIN EXPRESSION; RNA ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; 3' UNTRANSLATED REGION; ANIMAL; BINDING SITE; BONE NEOPLASMS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; SCID MOUSE; SECONDARY; TIME; TUMOR CELL LINE; TUMOR INVASION; YOUNG ADULT;

3' UNTRANSLATED REGIONS; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CREB-BINDING PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; STILBENES; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84923280243     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3088     Document Type: Article

References (60)

1. Osborne TS and Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012; 146(2-3): 132-142.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H and Winkler K. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3): 776-790.
3. Tsunemi T, Nagoya S, Kaya M, Kawaguchi S, Wada T, Yamashita T and Ishii S. Postoperative progression of pulmonary metastasis in osteosarcoma. Clin Orthop Relat Res. 2003; (407): 159-166.
4. Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009; 9(8): 1035-1049.
5. Yang D, Yu L and Van S. Clinically relevant anticancer polymer Paclitaxel therapeutics. Cancers (Basel). 2010; 3(1): 17-42.
6. Goa KL and Faulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging. 1994; 5(3): 200-234.
7. Felx M, Guyot MC, Isler M, Turcotte RE, Doyon J, Khatib AM, Leclerc S, Moreau A and Moldovan F. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond). 2006; 110(6): 645-654.
8. Yoon SO, Park SJ, Yun CH and Chung AS. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol. 2003; 36(1): 128-137.
9. Westermarck J and Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999; 13(8): 781-792.
10. Kang HG, Kim HS, Kim KJ, Oh JH, Lee MR, Seol SM and Han I. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness. J Orthop Res. 2007; 25(5): 696-702.
11. Himelstein BP, Asada N, Carlton MR and Collins MH. Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma. Med Pediatr Oncol. 1998; 31(6): 471-474.
12. Cakarovski K, Leung JY, Restall C, Carin-Carlson A, Yang E, Perlmutter P, Anderson R, Medcalf R and Dear AE. Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines. Int J Cancer. 2004; 110(4): 610-616.
13. Yang J and Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013; 25(4): 398-406.
14. Bjorklund M and Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005; 1755(1): 37-69.
15. Ambros V. The functions of animal microRNAs. Nature. 2004; 431(7006): 350-355.
16. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4): 259-269.
17. Li L and Li H. Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors. Cancer Biol Ther. 2013; 14(9): 796-805.
18. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008; 10(2): 202-210.
19. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA. MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009; 9(4): 293-302.
20. Baur JA and Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006; 5(6): 493-506.
21. Saiko P, Szakmary A, Jaeger W and Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res. 2008; 658(1-2): 68-94.
22. Lakshminarasimhan M, Rauh D, Schutkowski M and Steegborn C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging (Albany NY). 2013; 5(3): 151- 154.
23. Liu B and Zhou Z. Activation of SIRT1 by resveratrol requires lamin A. Aging (Albany NY). 2013; 5(2): 94-95.
24. Timmers S, Auwerx J and Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY). 2012; 4(3): 146-158.
25. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T, Lee MH, Xiao C, Vassilopoulos A, Chen W, Gardner K, Man YG, Hung MC et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008; 32(1): 11-20.
26. Melnikova VO, Mourad-Zeidan AA, Lev DC and Bar-Eli M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem. 2006; 281(5): 2911-2922.
27. Kim YS, Sull JW and Sung HJ. Suppressing effect of resveratrol on the migration and invasion of human metastatic lung and cervical cancer cells. Mol Biol Rep. 2012; 39(9): 8709-8716.
28. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn, AD, Mehta RG, Moon RC and Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997; 275(5297): 218-220.
29. Le Corre L, Chalabi N, Delort L, Bignon YJ and Bernard- Gallon DJ. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res. 2005; 49(5): 462-471.
30. Nguyen AV, Martinez M, Stamos MJ, Moyer MP, Planutis K, Hope C and Holcombe RF. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res. 2009; 1: 25-37.
31. Li Y, Backesjo CM, Haldosen LA and Lindgren U. Resveratrol inhibits proliferation and promotes apoptosis of osteosarcoma cells. Eur J Pharmacol. 2009; 609(1-3): 13-18.
32. Yang G, Yuan J and Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013; 30(4): 697.
33. Satpathy M, Shao M, Emerson R, Donner DB and Matei D. Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem. 2009; 284(23): 15390-15399.
34. Zhang D, Ma QY, Hu HT and Zhang M. beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther. 2010; 10(1): 19-29.
35. Shaywitz AJ and Greenberg ME. CREB: a stimulusinduced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999; 68: 821- 861.
36. Cho SJ, Chae MJ, Shin BK, Kim HK and Kim A. Akt- and MAPK-mediated activation and secretion of MMP-9 into stroma in breast cancer cells upon heregulin treatment. Mol Med Rep. 2008; 1(1): 83-88.
37. Garzon R, Marcucci G and Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9(10): 775-789.
38. Chaffer CL and Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331(6024): 1559-1564.
39. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004; 24(5A): 2783-2840.
40. Weng CJ and Yen GC. Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. Cancer Treat Rev. 2012; 38(1): 76-87.
41. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3: 895-904.
42. Mook OR, Frederiks WM and Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004; 1705(2): 69-89.
43. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer. 2003; 3(7): 489-501.
44. Qin H, Sun Y and Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem. 1999; 274(41): 29130-29137.
45. Nishihara H, Hwang M, Kizaka-Kondoh S, Eckmann L and Insel PA. Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J Biol Chem. 2004; 279(25): 26176-26183.
46. Kumashiro N, Tamura Y, Uchida T, Ogihara T, Fujitani Y, Hirose T, Mochizuki H, Kawamori R and Watada H. Impact of oxidative stress and peroxisome proliferatoractivated receptor gamma coactivator-1alpha in hepatic insulin resistance. Diabetes. 2008; 57(8): 2083-2091.
47. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998; 273: 32377- 32379.
48. Naqvi S, Martin KJ and Arthur JS. CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. Biochem J. 2014; 458(3): 469-479.
49. Chen PS, Su JL and Hung MC. Dysregulation of microRNAs in cancer. J Biomed Sci. 2012; 19: 90.
50. Sheth S, Jajoo S, Kaur T, Mukherjea D, Sheehan K, Rybak LP and Ramkumar, V. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One. 2012; 7(12): e51655.
51. Tili E, Michaille JJ, Adair B, Alder H, Limagne E, Taccioli C, Ferracin M, Delmas D, Latruffe N and Croce CM. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis. 2010; 31(9): 1561-1566.
52. Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW, Chen YH, Jan Y, Hsiao M, Chang TY, Liu YH, Jeng YM, Wu CH et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene. 2013; 32(4): 431-443.
53. Wang CH, Lee DY, Deng Z, Jeyapalan Z, Lee SC, Kahai S, Lu WY, Zhang Y and Yang BB. MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One. 2008; 3(6): e2420.
54. Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W and Yang Z. MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One. 2012; 7(10): e47270.
55. Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, Xiao SD and Ran ZH. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer. 2012; 106(7): 1320-1330.
56. Arora S, Ranade AR, Tran NL, Nasser S, Sridhar S, Korn RL, Ross JT, Dhruv H, Foss KM, Sibenaller Z, Ryken T, Gotway MB, Kim S et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer. 2011; 129(11): 2621-2631.
57. Jimenez E, Perez de la Blanca E, Urso L, Gonzalez I, Salas J and Montiel M. Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells. Biochem Biophys Res Commun. 2009; 380(4): 769-774.
58. Ho ML, Hsieh YS, Chen JY, Chen KS, Chen JJ, Kuo WH, Lin SJ and Chen PN. Antimetastatic Potentials of Dioscorea nipponica on Melanoma In Vitro and In Vivo. Evid Based Complement Alternat Med. 2011; 2011: 507920.
59. Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, Lai TC, Chang JS, Jan YH et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010; 70(20): 7830-7840.
60. Chen PN, Kuo WH, Chiang CL, Chiou HL, Hsieh YS and Chu SC. Black rice anthocyanins inhibit cancer cells invasion via repressions of MMPs and u-PA expression. Chem Biol Interact. 2006; 163(3): 218-229.